TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
TNG462-C103 is a Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat (PRMT5 inhibitor) in Combination with ERAS-0015 (pan-RAS molecular glue) in Patients with MTAP-null Pancreatic Cancer and MTAP-null Non-Small Cell Lung Cancer with RAS Mutation.
The study will be conducted in patients with MTAP- null pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic MTAP loss non-small cell lung cancer (NSCLC) with RAS mutation in 2 parts: Phase 1 (dose escalation) and Phase 2 (dose expansion).
Individual arms in dose expansion may open once the MTD and/or RD(s) has been determined for the corresponding combination in dose escalation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Is ≥18 years of age at the time of signature of the main study ICF.
2. Has an ECOG PS of 0 or 1.
3. Has loss of the MTAP gene, documented by a validated assay
4. Has one of the following disease characteristics:
* 1L or 2L metastatic PDAC
* Locally advanced, recurrent or metastatic NSCLC (no more than 2 prior lines of therapy) with documented KRAS mutation at G12X or G13X locally obtained via an analytically validated assay (Dose expansion only).
5. Has evidence of measurable disease based on RECIST v1.1.
6. Adequate organ function
You may not be if
1. Has received prior treatment with a PRMT5 inhibitor, MAT2A inhibitor or RAS inhibitor.
2. Has an active infection requiring systemic therapy.
3. Any condition that may impact the ability to take or absorb study drugs
4. Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms